A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Inclusion Criteria (All groups): * Male or female subjects between ≥18 years and ≤70 years of age * Have a body weight ≥45 kg and body mass index (BMI) ≥18.5 kg/m2 to 40.0 kg/m2 Additional Group-Specific Inclusion Criteria: * Group 1 (Moderate Hepatic Impairment Subjects): * Presence of Moderate hepatic impairment (Child-Pugh Class B) * Group 2 (Normal Hepatic Function Subjects): * Normal hepatic function * Group 3 (Mild Hepatic Impairment Subjects): * Presence of mild hepatic impairment ( Child-Pugh Class A) Exclusion Criteria (all groups): * Renal impairment ≥ Stage 3 (estimated glomerular filtration rate \[eGFR\] \<60 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) study equation) * Any history of active malignancy within 2 years prior to or during screening, except for treated basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or cervical carcinoma in situ; any history of tuberculosis and/or prophylaxis for tuberculosis * Positive test for human immunodeficiency virus (HIV) antibody at Screening. * Hepatic or other organ or cell transplant * Subjects with alcoholic cirrhosis must be sober for a minimum of 6 months